Agilent acquires Lab901
Edinburgh-based electrophoresis equipment and consumables company, Lab901, has been acquired by Agilent Technologies for an undisclosed amount.
Edinburgh-based electrophoresis equipment and consumables company, Lab901, has been acquired by Agilent Technologies for an undisclosed amount.
"With the addition of Lab901's outstanding technology and talented team, Agilent can now address customer needs across the entire span of electrophoresis life science applications — from semi-automated to 96-well-plate compatible workflows," said Patrick Kaltenbach, vice president of Agilent's Liquid Phase Separations business. "Alongside our existing BioAnalyzer platform and the Agilent G7100 Electrophoresis System, the Lab901 ScreenTape system provides a very versatile, automated and scalable throughput gel electrophoresis solution for a wide range of applications."
Lab901 develops and markets benchtop electrophoresis instruments, plastic-based consumables and associated reagents, used in pharma, bio-pharma R&D and quality control for DNA, RNA and protein analysis.
"We have always recognized the strong synergy between our two companies," said Joel Fearnley, Lab901's former CEO, who will join Agilent Technologies along with the rest of his employees. "We look forward to offering our global customers an unrivalled portfolio of advanced products to address their electrophoresis needs."
For more information about the companies go to www.agilent.com and www.lab901.net
The Complexity of Oligonucleotide Separations
January 9th 2025Peter Pellegrinelli, Applications Specialist at Advanced Materials Technology (AMT) explains the complexity of oligonucleotide separations due to the unique chemical properties of these molecules. Issues such as varying length, sequence complexity, and hydrophilic-hydrophobic characteristics make efficient separations difficult. Separation scientists are addressing these challenges by modifying mobile phase compositions, using varying ion-pairing reagents, and exploring alternative separation modes like HILIC and ion-exchange chromatography. Due to these complexities, AMT has introduced the HALO® OLIGO column, which offers high-resolution, fast separations through its innovative Fused-Core® technology and high pH stability. Alongside explaining the new column, Peter looks to the future of these separations and what is next to come.
Metabolomics Analysis of Low Birth-Weight Infants Using UHPLC-MS/MS Following Lipid Emulsion
January 10th 2025A recent study aimed to directly compare the changes in serum metabolites among very low birth-rate (VLBW) infants following the administration of the soybean oil-based lipid emulsion and soybean oil, medium-chain triglycerides, olive oil, and fish oil (SMOF) lipid emulsion using untargeted metabolomics techniques.
Analyzing New Drug Modalities: An ISC 2024 Interview with Kelly Zhang
January 10th 2025At ISC 2024 in Liverpool, United Kingdom, LCGC International interviewed Kelly Zhang of Genentech about her work analyzing new drug modalities, such as mRNA, oligonucleotides, peptides, and cell and gene therapies.
